Pfizer Inc. (PFE)
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes
13-week data from the Viking Therapeutics, Inc. phase 2 VENTURE-Oral Dosing trial using oral VK2735 for the treatment of patients with obesity, expected 2nd half of 2025. Pfizer's recent setbacks in weight-loss drugs may prompt it to consider acquiring VKTX, adding VK2735 and VK2809 to its pipeline. VK2735's dual administration routes and dual GLP-1/GIP agonist mechanism position it as a strong contender in the growing $37.94 billion anti-obesity market.
Pfizer Halts Obesity Pill Development Amid Safety Concerns
PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Bad news for Pfizer (PFE 1.07%) turned into good news for Eli Lilly (LLY 2.42%), Novo Nordisk (NVO 2.23%), and Viking Therapeutics (VKTX 8.48%) Monday morning, each of which is rising on Pfizer's latest product announcement.
Biotech Stock A Big Winner After Pfizer Halts Weight-Loss Drug
Viking Therapeutics Inc (NASDAQ:VKTX) stock is up 10.1% to trade at $24.42 today, and traded as high as $27.09 earlier in the session.
Pfizer Halts Development of Obesity Drug After Patient Sustains 'Liver Injury'
Pfizer (PFE) said it will stop development of an oral daily weight-loss pill after a participant taking the drug in a clinical trial experienced a liver injury.
Pfizer discontinues development of weight loss pill
Pfizer Inc (NYSE:PFE, ETR:PFE) announced it will discontinue the development of its experimental weight-loss pill, danuglipron, due to safety concerns. The company said on Monday that the decision comes after a clinical trial participant experienced a potential drug-induced liver injury, which resolved after stopping the medication.
Pfizer scraps daily weight loss pill after liver injury in one patient
Pfizer said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial. The patient's liver enzymes "recovered rapidly" after they stopped taking the pill, which is an oral GLP-1 drug called danuglipron.
Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant
Danuglipron was the latest drug investors were hinging hope on to enter the obesity market.
Pfizer Halts Development of New Weight-Loss Drug
The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.
1 Deeply Undervalued Stock to Buy in the Market Correction
Pfizer's (PFE 1.39%) shares have been southbound for the better part of three years, partly because it was unable to repeat its incredible financial performance during the early pandemic years. However, the company took another dive this year along with the broader market; President Donald Trump's trade wars are leaving few stocks completely unscathed.
Pfizer (PFE) Advances But Underperforms Market: Key Facts
Pfizer (PFE) closed the most recent trading day at $21.91, moving +1.48% from the previous trading session.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
